Skip to content
Search

Latest Stories

UK issues recall of antidepressant tablets after packaging error

The action follows a patient complaint after a sealed carton of sertraline was found to contain one blister strip of Citalopram 40mg tablets.

​Amarox

Amarox Limited said it is recalling one batch of Sertraline 100mg film-coated tablets as a precaution.

MHRA

A BATCH of antidepressant medication in the UK has been recalled after a packaging error led to the wrong tablets being included in some packs.

Amarox Limited said it is recalling one batch of Sertraline 100mg film-coated tablets as a precaution.


The action follows a patient complaint after a sealed carton of sertraline was found to contain one blister strip of Citalopram 40mg tablets.

Sertraline and citalopram are both selective serotonin reuptake inhibitors used to treat depression, anxiety disorders and related conditions by increasing serotonin levels in the brain. Both medicines are produced by the same manufacturer at the same site. The issue has been linked to an error during the packaging of blister strips into cartons.

Patients in the UK who may have taken Citalopram 40mg tablets by mistake or are experiencing side effects have been advised to seek medical advice.

Dr Alison Cave, MHRA Chief Safety Officer, said: “If you have been prescribed Sertraline 100mg tablets and have received batch number V2500425, please check the carton contains the right medication. You can find the batch number and expiry date printed on the side of the outer packaging.

“If the blister strips inside the carton are labelled Citalopram 40mg, please contact your pharmacy as soon as possible. If they are labelled Sertraline 100mg, no further action is needed.”

“Patients who have accidentally taken citalopram instead of - or as well as - sertraline may experience some heightened serotonergic side effects. These can include nausea, headache, sleep changes and mild anxiety.”

Pharmacists and other healthcare professionals have been asked to contact affected patients and return any remaining stock. The MHRA has also advised stopping supply of the affected batch and returning it to suppliers. Suspected adverse reactions should be reported through the MHRA Yellow Card scheme.

More For You

A not happy young girl

Around 51 per cent of those aged 15 to 19 are already estimated to be living with a mental or behavioural disorder

iStock (Photo for representation)

5 drivers behind the mental health crisis as two-thirds of UK teens are at risk

  • Nearly 64 per cent of UK teenagers could face mental health issues by 2030
  • More than 10.5 million Britons are expected to suffer from anxiety by 2028
  • Only 53 per cent of people with mental health conditions are currently in work

The scale of the problem is becoming harder to ignore. A new report from Zurich Insurance suggests that mental health conditions are no longer an outlier among British teenagers but increasingly the norm. Around 51 per cent of those aged 15 to 19 are already estimated to be living with a mental or behavioural disorder, ranging from anxiety and depression to ADHD. If current trends continue, that figure could rise to 64 per cent by 2030.

The implications go beyond health. Policymakers are beginning to link this surge to broader economic risks, particularly youth unemployment. Nearly one million young people aged 16 to 24 in the UK are already classified as not in education, employment or training, and experts warn that worsening mental health could deepen this challenge. Only 53 per cent of Britons with a mental health condition are in work, compared with 82 per cent of those without, according to Zurich’s findings.

Keep ReadingShow less